NCT06062810 2026-04-09
Drugs-SNPs
Medicine Invention Design, Inc
Phase 2/3 Active not recruiting
Clinical Trials
4 trialsNCT03315364 2026-04-01
OPTIMAL
Daehwa Pharmaceutical Co., Ltd.
Phase 2/3 Active not recruiting
NCT06926868 2026-04-01
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT07294508 2026-03-20
A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
Shanghai Henlius Biotech
Phase 2/3 Recruiting